BioNTech SE Files 6-K with Purchase Agreement Details

TL;DR

BioNTech SE signed a purchase agreement on June 12, 2025, details in new 6-K filing.

AI Summary

On June 12, 2025, BioNTech SE entered into a Purchase Agreement, the details of which are included as part of this Form 6-K filing. The company is a European stock corporation organized under the laws of Germany and the European Union.

Why It Matters

This filing provides insight into BioNTech's recent contractual activities, which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a purchase agreement and does not indicate any immediate financial distress or significant operational changes.

Key Players & Entities

• BioNTech SE (company) — Registrant and Buyer in the Purchase Agreement
• June 12, 2025 (date) — Date of the Purchase Agreement

FAQ

From the Filing

0001193125-25-142077.txt : 20250617 0001193125-25-142077.hdr.sgml : 20250617 20250617161716 ACCESSION NUMBER: 0001193125-25-142077 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250617 FILED AS OF DATE: 20250617 DATE AS OF CHANGE: 20250617 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 251053519 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 d43024d6k.htm 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ☒   Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K Purchase Agreement As previously announced, on June 12, 2025, BioNTech SE (“ Buyer ”), a European stock corporation ( Societas Europaea ) organized under the laws of Germany and the European Union, and CureVac N.V. (the “ Company ”), a public limited liability company ( naamloze vennootschap ) organized under the laws of The Netherlands, entered into a purchase agreement (the “ Purchase Agreement ”). The Purchase Agreement provides for Buyer’s acquisition of the Company through a public exchange offer, followed by a series of post-offer reorganization steps. Initial Offer, Duration and Expiration Time Pursuant to the Purchase Agreement, Buyer will commence an exchange offer (as it may be amended from time to time as permitted by the Purchase Agreement, the “ Offer ”) to purchase any and all of the ordinary shares, par value €0.12 per share, of the Company (the “ Company Shares ”) in exchange for a number of American Depositary Shares of Buyer, each representing one ordinary share of Buyer with a notional amount of €1.00 (a “ Buyer ADS ”), equal to the quotient rounded to five decimal places (the “ Exchange Ratio ”) obtained by dividing (i) $5.4641 by (ii) the volume-weighted average price per Buyer ADS taken to four decimal places over the 10 consecutive trading day-period concluding with the market closing trade on Nasdaq on the fifth trading day immediately preceding the Expiration Time (as defined below) (the “ Buyer ADS VWAP ”), provided, however, that (i) if the Buyer ADS VWAP is greater than or equal to $126.55, then the Exchange Ratio will be 0.04318, and (ii) if the Buyer ADS VWAP is less than or equal to $84.37, then the Exchange Ratio will be 0.06476, in each case without interest (the “ Offer Consideration ”). The Offer will remain open until 9:00 a.m. (New York City time) on the day that is the later of • the 21st business day following the commencement of the Offer, and • the third business day following the date of the extraordinary general meeting of the shareholders of the Company discussed below (the “ EGM ”), unless the Offer is exte